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A Novel TNF Receptor Family Member Binds TWEAK
and Is Implicated in Angiogenesis
death domain in its cytoplasmic tail and can induce
apoptosis (Marsters et al., 1998). We have been unable
to reproduce these results by using similar techniques.
Steven R. Wiley1,4, Linda Cassiano1, Timothy Lofton1,
Terry Davis-Smith1, Jeffrey A. Winkles2,
Volkhard Lindner3, Hua Liu1,
Thomas O. Daniel1, Craig A. Smith1, In addition, TWEAK-DR3 interaction could not be con-
firmed using slide binding assays performed either byand William C. Fanslow1
1 Immunex Corporation overexpressing TWEAK in transfected cells and probing
with DR3-IgG-Fc fusion protein, or by overexpressing51 University Street
Seattle, Washington 98101 DR3 in transfected cells and probing with TWEAK (data
not shown). In agreement with these findings, recently2 Department of Vascular Biology
Holland Laboratory published studies indicate that TWEAK does not bind
DR3 and that a receptor specific for TWEAK must existAmerican Red Cross
Rockville, Maryland 20855 (Schneider et al., 1999; Kaptein et al., 2000).
In this paper we report the identification of a member3 Center for Molecular Medicine
Maine Medical Center Research Institute of the TNF receptor family, TweakR, which binds to
TWEAK with high affinity. Members of the TNF receptorScarborough, Maine 04106
family can be identified by a distinctive set of cysteine-
rich repeat regions in the extracellular domain (reviewed
in Locksley et al., 2001). Most receptors have three toSummary
four of these regions, although some, such as the recep-
tors for TRAIL/Apo2L and TACI have only two. OneTWEAK is a member of the TNF ligand family that
induces angiogenesis in vivo. We report cloning of a known member of the TNF receptor family, BCMA, has
been described that has only one such region (Madryreceptor for TWEAK (TweakR) from a human umbilical
vein endothelial cell (HUVEC) library. The mature form et al., 1998). TweakR also has just one cysteine-rich
region in the extracellular domain, and with a total aminoof TweakR has only one hundred and two amino acids
and six cysteine residues in its extracellular region. acid count of 102 (after signal peptide cleavage), it is the
smallest TNF receptor family member so far described.Five different assays demonstrate TWEAK-TweakR
binding, and the interaction affinity constant (Kd) is While this manuscript was in preparation, Feng et al.
(2000) reported the cloning, chromosomal location, andwithin a physiologically relevant range of 2.3 0.1 nM.
The TweakR cytoplasmic domain binds TRAFs 1, 2, expression properties of a human gene named Fn14.
The Fn14 and TweakR nucleotide sequences have 100%and 3. Cross-linking of TweakR induces HUVEC
growth, and mRNA levels are upregulated in vitro by identity. The Fn14 gene was first identified using a differ-
ential display approach to search for growth factor-a variety of agents and in vivo following arterial injury.
Soluble TweakR inhibits endothelial cell migration in inducible genes in murine NIH 3T3 fibroblasts, and Fn14
itself was shown to be a plasma membrane-anchoredvitro and corneal angiogenesis in vivo.
protein (Meighan-Mantha et al., 1999). However, due to
the degree of amino acid sequence divergence fromIntroduction
other TNF receptor family members, Fn14 was not clas-
sified as a member of the TNF receptor family. Here weTWEAK is a member of the TNF family of cytokines that
was first described as a weak inducer of apoptosis in demonstrate that this relatively small molecule is a fully
functional member of the TNF receptor family able totransformed cell lines (Chicheportiche et al., 1997).
TWEAK induces IL-8, IL-6, and ICAM-I expression in transduce a signal to its host cell, and implicate TweakR
in a variety of vascular cellular responses both in vitrocultured human astrocytes (Saas et al., 2000), and cul-
tured monocytes have been shown to respond to IFN- and in vivo.
by inducing surface expression of TWEAK (Nakayama
et al., 2000). TWEAK mRNA expression is also downreg- Results
ulated in murine models of inflammation (Chicheportiche
et al., 2000). In addition, TWEAK induces proliferation Expression Cloning of TweakR from HUVECs
of human smooth muscle and endothelial cells in vitro, An expression cloning panning approach was used to
and acts as a potent inducer of angiogenesis in a rat identify a TWEAK binding receptor expressed in HUVEC.
cornea pocket angiogenesis assay (Lynch et al., 1999). Magnetic beads were coated with the C-terminal recep-
Given the involvement of TWEAK in inflammation mod- tor binding domain of TWEAK and used for two rounds
els and its expression pattern on monocytes it is impor- of panning of COS cells transfected with a HUVEC cDNA
tant to identify the receptor for TWEAK in order to better expression library. The resulting enriched pool was fur-
elucidate its role in the immune as well as angiogenic ther broken down by slide binding (Goodwin et al., 1993),
systems. in order to identify a single clone encoding the TWEAK
It was reported previously that TWEAK binds to DR3, binding activity. Sequence analysis of the recovered
a member of the TNF receptor family that contains a clone predicted TweakR to be a type-I transmembrane
protein with a single extracellular cysteine-rich region
comprising six cysteine residues in its extracellular do-4 Correspondence: wileys@immunex.com
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Figure 1. Features and Homology of Predicted TweakR Primary Amino Acid Sequence
(A1) Predicted primary amino acid sequence of TweakR showing major features. The leader sequence in underlined. The arrow indicates the
predicted site of cleavage of the leader sequence. The region of TNF family receptor homology is shown in bold. The predicted transmembrane
region is doubly underlined. The putative TRAF binding motif in the cytoplasmic domain is boxed.
(A2) Alignment of TweakR to selected cysteine-rich domains of other members of the TNF receptor family. The family member and cysteine-
rich domain number are indicated on the left. Boxes emphasize aligned cysteines.
(B) Slide binding showing qualitative interaction of TweakR with TWEAK. Shown is an autoradiographic image of Cos cells transfected with
TweakR versus control vector and probed with TWEAK-LZ and 125I-labeled M15 antileucine zipper antibody (1 and 2, respectively), or CV1-
EBNA cells transfected with human full-length TWEAK versus control vector and detected with TweakR-Fc and 125I-labeled goat antimouse
IgG antibody (3 and 4, respectively).
(C) CV-1 cells transfected with human full-length TWEAK were mixed at a 1:30 ratio with Raji cells and incubated with various concentrations
of 125I-labeled TweakR-Fc as described in the Experimental Procedures. Shown is a Scatchard representation of specific binding. (Inset) Plot
of competitive inhibition of unlabeled verses 125I-labeled TweakR-Fc.
main (Figure 1, A1). An alignment of the cysteine-rich TWEAK. The intrinsic affinity between TWEAK ligand
and receptor was estimated by measuring the equilib-extracellular region with the cysteine-rich region of other
TNF receptor family members revealed a weakly con- rium binding constant between TweakR-Fc and recom-
binant full-length surface ligand transiently expressedserved pattern of extracellular cysteines (Figure 1, A2).
The predicted twenty-eight amino acid cytoplasmic do- on CV1/EBNA cells. Direct binding of 125I-TweakR-Fc to
surface ligand, plotted in Scatchard format (Figure 1C),main contains a region, which bears resemblance to
known binding sites for TRAF family signaling molecules gave an affinity constant of 2.3 0.1 nM. Consistent with
this value, competitive inhibition assays with unlabeled(see below). Aside from the cysteine pattern, and the
putative TRAF binding site, there is virtually no sequence TweakR-Fc gave a K(I) of 2.5 0.1 nM (Figure 1C, inset).
Confirmation that TweakR is largely responsible forconservation between TweakR and other TNF receptor
family members. TWEAK-TweakR interaction was quali- TWEAK binding to native cells was demonstrated by
the ability of a monoclonal antibody against TweakR totatively confirmed by slide-binding assays conducted
by either transfecting the isolated TweakR cDNA clone significantly inhibit binding of TWEAK to endothelial
cells as measured by flow cytometry (data not shown).into cells and detecting with TWEAK-LZ and 125I-labeled
antileucine zipper antibody, or conversely by transfect- Together these experiments represent five independent
experimental approaches demonstrating a TWEAK-ing a full length TWEAK cDNA clone into cells and de-
tecting by TweakR-Fc and 125I-goat antihuman IgG anti- TweakR interaction.
body (Figure 1B).
The TweakR Cytoplasmic Domain Binds
TWEAK Ligand-Receptor Affinity TRAF1, 2, and 3
Many TNF receptor family members have been shown toGiven the unusually small size of TweakR, and the lack
of strong similarity to other TNF family receptors, it was bind members of the TRAF family of signal transduction
molecules. This, combined with the observation thatnecessary to determine the affinity of its interaction with
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cell. For example, it is formally possible that TweakR
actually inhibits rather than promotes TWEAK signaling.
In order to investigate whether or not the molecule re-
sulting from the panning experiment was a functional
receptor, a construct was made that fuses a synthetic
Flag octapeptide epitope onto the N-terminal extracellu-
lar domain of TweakR (Flag-TweakR). The resulting pro-
tein was expressed by transient transfection in HUVEC
and incubated with cross-linked antiFlag monoclonal
antibody. Cross-linking the receptor in this manner
avoids background from the endogenous TweakR ex-
pressed by HUVEC. Proliferation was measured by BrdU
incorporation into DNA. Lipid mediated transfection of
HUVEC with Flag-TweakR resulted in expression of re-
combinant Flag-TweakR on the cell surface by 36 hr
posttransfection. The Flag-TweakR was expressed at a
high level by 9% of the transfected HUVEC used in these
experiments, with a mean fluorescence intensity (MFI)
of 99 compared to the MFI of the vector only HUVECs
of 4.5. The results are expressed as the fold increase
in the number of BrdU positive cells (BrDU mAb-FITC
positive cells) under each culture condition over the
Figure 2. Qualitative Binding of TRAFs to the TweakR Cytoplasmic
number of negative-control FITC positive cells. In vitroDomain
culture of Flag-TweakR expressing HUVEC with theIndicated TRAF molecules were 35S-labeled by coupled in vitro tran-
complex of M2 antiFlag and goat antimouse IgG in-scription/translation and incubated with GST beads (C), GST-
creased BrdU incorporation 3-fold over the level of BrdUTweakR cytoplasmic domain fusion beads (T), or GST-RANK cyto-
plasmic domain fusion beads (R). Beads were washed and the incorporation observed by culturing Flag-TweakR ex-
bound TRAF molecules were resolved by SDS-PAGE and visualized pressing cells with goat antimouse IgG alone (Figure
by autoradiography. 3). Culture of Flag-TweakR expressing HUVEC with the
complex of M2 antiFlag and goat antimouse IgG in-
creased BrdU incorporation 6-fold over the level of BrdU
the TweakR cytoplasmic domain contains a region that incorporation observed by culturing vector alone-trans-
resembles TRAF binding motifs found in many TNF fam- fected HUVEC with the cross-linking complex. Incuba-
ily receptors, led us to qualitatively test the ability of tion with the cross-linking complex did not alter BrdU
this region to bind to various members of the TRAF incorporation in vector alone-transfected HUVEC. The
family. The 28 amino acid TWEAK cytoplasmic domain 2 increase in BrdU incorporation between cells ex-
was fused to glutathione S-transferase (GST) and then pressing Flag-TweakR relative to control cells in the
bound to glutathione-Sepharose beads. Control beads absence of cross-linking is likely because of a low level
bound with GST lacking the TweakR cytoplasmic do- of spontaneous signaling due to overexpresson of the
main were used to determine background levels of bind- receptor. These data provide direct evidence that de-
ing. Beads bound with the cytoplasmic domain of the spite its small size, TweakR is capable of initiating a
TNF receptor family member RANK fused to GST were proliferative signal in human endothelial cells.
used as a positive control. This RANK-GST fusion con-
struct is a high affinity TRAF binder that contains two
Regulation of TweakR mRNA Expressionsites for TRAF interaction and binds to TRAF1, 2, 3, 5,
in Vascular SMCand 6 (Galibert et al., 1998). The beads were incubated
Previous studies have demonstrated that growth factorwith in vitro translated 35S-labeled TRAF proteins. The
stimulation of quiescent murine or human fibroblastsresults show that under the conditions used TRAF1 and
promotes a transient increase in TweakR (Fn14) geneTRAF2 can interact with the TWEAK cytoplasmic region
expression (Meighan-Mantha et al., 1999; Feng et al.,GST coated beads above background levels (Figure 2).
2000). In consideration of the ability of TWEAK to stimu-TRAF3 binding is weaker, but still above background
late proliferation of endothelial and smooth muscle cellslevels. TRAF4 and TRAF6 showed no binding to the
(Lynch et al., 1999), we investigated whether TweakRTweakR cytoplasmic domain above background levels.
gene activation also occurred in mitogen-stimulatedTRAF5 did not express well in our in vitro system, and
vascular cells. First, rat aortic SMC were serum-starvedtherefore the binding of this protein to the TweakR cy-
and then treated with FGF-2 for various lengths of time.toplamic tail could not be evaluated.
RNA was isolated and TweakR mRNA levels were exam-
ined by Northern blot hybridization. A single TweakR
transcript of 1.2 kb in size was detected in SMC.Cross-Linking of TweakR Transmits a Proliferative
Signal to HUVEC TweakR mRNA expression was transiently induced fol-
lowing FGF-2 addition, with maximal levels detected atAlthough TweakR binds to TWEAK with an affinity that is
consistent with other TNF ligand-receptor interactions, 2 hr post-stimulation (Figure 4A). Second, we treated
serum-starved SMC for 4 hr with various agents (e.g.,these data do not demonstrate that TweakR functions
as a receptor, which can transduce a signal into the host phorbol ester, polypeptide growth factors, peptide
Immunity
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Figure 3. BrdU Incorporation into HUVECs Transfected with Either Empty Vector (pDC412) or a Flag Epitope-Tagged TweakR
Triplicate cultures of cells transfected as indicated were incubated in media containing goat-antimouse IgG in either the presence or absence
of M2 antiFlag mAb. The results are expressed as the mean fold increase  SEM in BrdU positive cells compared to control for each culture
condition.
hormones), and then performed Northern blot analysis EGF, FGF-2, or Ang II treatment of rat SMC (Figure 4B).
In comparison, TGF-1, IGF-1, or -thrombin treatmentto determine whether TweakR gene expression could
be induced by multiple, distinct, growth promoters. had only a slight stimulatory effect. These results indi-
cate that TweakR is a growth factor-regulated gene inTweakR mRNA levels were significantly elevated above
unstimulated levels following PMA, FBS, PDGF-BB, vascular SMC.
Figure 4. Regulation of TweakR mRNA Expression in Rat Aortic SMC
(A) Serum starved cells were either left untreated (0) or treated with FGF-2 for the indicated time periods. RNA was isolated, and equivalent
amounts of each sample were analyzed by Northern blot hybridization using the two cDNA probes indicated. The positions of 28S and 18S
rRNA are noted on the left with tick marks.
(B) Serum starved cells were either left untreated (NT, no treatment) or treated with phorbol myristate acetate (PMA), fetal bovine serum (FBS),
PDGF-BB, TGF-1, EGF, IGF-1, FGF-2, -thrombin, or angiotensin II (Ang II) for 4 hr. RNA was isolated, and equivalent amounts of each
sample analyzed by Northern blot hybridization.
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Figure 5. Photomicrographs of En Face Preparations of Rat Aortae Examined for TweakR Expression by In Situ Hybridization with 35S-UTP
Labeled Antisense and Sense Probes
(A) The uninjured aorta showed low levels of TweakR expression in the endothelium.
(B) Proliferating and migrating endothelium at the wound edge 8 days after aortic injury revealed upregulated expression of TweakR. The still
denuded area is located on the right.
(C) Strong expression of TweakR mRNA was seen in proliferating SMC forming the neointima at 8 days following balloon injury.
(D) Hybridization with the sense probe showed very little background hybridization in SMC 8 days after injury. Hematoxylin was used for
staining nuclei, and all specimens were viewed under dark field illumination at 200 original magnification.
TweakR mRNA Expression in Injured Rat Arteries TweakR-Fc Inhibits Migration of HRMECs In Vitro
Angiogenesis is a multi-step process that requires notA common clinical situation that involves proliferation
of both smooth muscle and endothelial cells results from only proliferation, but also morphological alterations and
migration of vascular cells. Therefore, the effect ofvessel damage induced by balloon angioplasty. There-
fore, we examined TweakR mRNA expression following blocking TweakR signaling on endothelial cell migration
was tested by use of an in vitro planar endothelial cellballoon catheter denudation of rat carotid arteries.
In situ hybridization of en face preparations using migration (wound closure) assay (Daniel et al., 1999). In
this assay, migration of primary human renal microvas-35S-labeled riboprobes allowed us to compare TweakR
mRNA expression levels in quiescent vs. proliferating cular endothelial cells (HRMEC) is measured by the rate
of closure of a circular wound in a cultured cell mono-EC, and also to examine TweakR mRNA expression in
SMC accumulating on the luminal surface after injury. layer. The rate of wound closure is linear, and is dynami-
cally regulated by agents that stimulate and inhibit angi-We found that endothelium from uninjured arteries ex-
pressed low levels of TweakR mRNA (Figure 5A); how- ogenesis in vivo. By fusing the extracellular portion of
TweakR to the human IgG1-Fc domain (TweakR-Fc), aever, significantly higher levels of expression were de-
tected in proliferating EC at the wound edge (Figure 5B). soluble inhibitor of TweakR signaling was created. Two
stimuli were used to increase the rate of closure of theIn addition, high levels of TweakR mRNA expression
were found in proliferating, intimal SMC at 8 days after HRMEC: PMA or EGF (Figure 6A and 6B). TweakR-Fc
inhibited PMA-stimulated endothelial cell migration in ainjury (Figure 5C). All en face preparations probed with
a 35S-labeled TweakR sense riboprobe as a control re- dose responsive manner, reducing the rate of migration
to near basal levels at 1.5 g/ml. Neither huIgG-Fc norvealed low levels of hybridization (Figure 5D). These
results indicate that TweakR mRNA expression is upreg- TweakR-Fc added alone inhibited basal (uninduced) mi-
gration (Figure 6A). EGF-induced HRMEC migration wasulated in proliferating EC and SMC in vivo.
Immunity
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Figure 6. Human TweakR-Fc Inhibits PMA- or EGF-Stimulated Endothelial Cell Migration In Vitro
(A) At the time of wound initiation, basal media was supplemented with PMA, PMA  huIgG-Fc, PMA  titrated TweakR-Fc, huIgG-Fc alone,
or huTweakR-Fc alone at the concentrations indicated. After 12 hr of incubation the means of the residual wound areas, expressed as fractions
of the original wound, were converted into migration rate (expressed as the percentage of the original wound area covered per hour). The
results expressed in the columns are the mean migration rate for each condition (triplicate cultures) at 12 hr  SEM (error bars).
(B) At the time of wound initiation, basal media was supplemented with EGF, EGF  huIgG-Fc, EGF  titrated TweakR-Fc, huIgG-Fc alone,
or TweakR-Fc alone at the concentrations indicated. The experiment was performed and analyzed as described in (A).
similarly inhibited by TweakR-Fc, reducing the rate of tein IgG-Fc. This demonstrates that TweakR signaling
plays a role in certain types of angiogenesis in vivo.migration to unstimulated levels at 5 g/ml (Figure 6B).
These results indicate that endogenous TWEAK regu-
lates endothelial cell wound closure rate in this assay.
Discussion
The results presented here describe the identificationTweakR-Fc Inhibits FGF-2-Stimulated Corneal
Angiogenesis In Vivo and initial functional characterization of a receptor for
TWEAK in endothelial cells. The TweakR is a type-IIn order to test the relevance of signaling by TweakR in
vivo, TweakR-Fc was tested for its ability to inhibit FGF- transmembrane protein of 128 amino acids in length,
making it the smallest of all known TNF receptor family2-induced angiogenesis in a mouse cornea pocket
assay (Figure 7). In this assay, agents to be tested for members. It has only one cysteine-rich domain in the
extracellular region, a feature shared with just one otherangiogenic or antiangiogenic activity are immobilized in
a slow release form in a hydron pellet, which is implanted known TNF receptor, BCMA (Madry et al., 1998). The
short 28 amino acid putative cytoplasmic domain con-into micropockets created in the corneal epithelium of
anesthetized mice. Quantitation is measured by photog- tains a sequence that is similar to TRAF binding motifs
found in other TNF family receptors. However, theseraphy using a slit-lamp microscope followed by analysis
with image processing software. Vascularization is mea- features are only clear in hindsight. Based on the primary
amino acid sequence alone, it is very difficult to identifysured as the area, density, and extent of vessel growth
from the vascularized corneal limbus into the normally TweakR as a member of the TNF receptor family, or
even as a receptor of any kind. An alignment of theavascular cornea. The results show that local adminis-
tration of TweakR-Fc (100 pmol) inhibited FGF-2-stimu- cysteine-rich region of TweakR with those of other TNF
receptor family members demonstrates the high degreelated corneal angiogenesis (Figure 7A), reducing the
vascular area to 50% of that induced by FGF-2 alone of divergence from other family members (Figure 1, A2).
Despite this unusually small extracellular domain, andor FGF-2 plus control-IgG-Fc (Figure 7B). In addition to
reducing vascular area, local administration of TweakR- divergence in the cysteine-rich repeat region, the Ka of
TWEAK-TweakR interactions (4.2  108 M	1) is similarFc significantly inhibited FGF-2-stimulated induced ves-
sel density (imaged on hemoglobin) by 70% compared to the affinity of CD30 to its receptor (4.0  108) when
measured the same way (Smith et al., 1993). Althoughto the vessel density in the presence of the control pro-
Receptor for TWEAK Is Implicated in Angiogenesis
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Figure 7. TweakR-Fc Treatment Reduces FGF-2-Stimulated Corneal Angiogenesis in the Mouse
(A) Representative photographs illustrating corneal vessel growth in vehicle only containing pellets as compared to localized administration
of FGF-2 and concomitant administration of FGF-2 and TweakR-Fc.
(B) The results were quantified as described in Experimental Procedures. The fractional vascularized area of the cornea and the total vascular
density within the corneal perimeter induced by FGF-2 in the presence of no inhibitor, huIgG or TweakR-Fc is shown (columns 
 mean, error
bars 
 SEM). A significant decrease in new corneal vessels is observed with concomitant administration of FGF-2 and TweakR-Fc (p 

0.0028). Values for each experimental condition are obtained from a total of nine separate animals.
this affinity is approximately 20-fold less than that mea- transduces a proliferative signal into the cell following
receptor cross-linking (Figure 3). Cross-linking via ansured for TNF binding to TNF-R1, it is still in the physio-
logical range for this family of ligand-receptor cognates. extracellular artificial epitope, rather than using the natu-
ral ligand, ensures that the increase in proliferation isAlso, the binding curve produced by the analyses is a
monovalent curve, as opposed to the bivalent curve due to signaling by TweakR, as opposed to some other
hypothetical receptor for TWEAK. Therefore, despite itssometimes seen in similar analyses with other TNF fam-
ily members. This indicates that only one type of binding small cytoplasmic region, TweakR is a functioning re-
ceptor.site was detected, rather than a mixture of high and low
affinity sites. Northern blot analyses show that TweakR gene ex-
pression is rapidly upregulated in smooth muscle cellsThe 28 amino acid cytoplasmic domain of TweakR is
also much smaller than many other receptors in the by a variety of agents and known growth factors (Figure
4). This leaves open the possibility that TweakR mightfamily. Nevertheless, the cytoplasmic region is capable
of binding TRAF family members 1, 2, and 3 (Figure 2). be involved in a range of biological activities. One such
activity is endothelial cell migration, which is a neces-Although this does not rule out other potential signaling
pathways, one possible mechanism for TweakR signal- sary component of angiogenesis. The rate of wound
closure in a HRMEC monolayer is enhanced by multipleing is through the TRAF family of adaptor proteins. After
transfection into endothelial cells, full-length TweakR stimuli such as PMA and EGF. Blocking TweakR reduces
Immunity
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this enhanced rate of wound closure back to unstimu- both in vitro and in vivo, supports the hypothesis that
lated levels (Figure 6). Presumably, this is due to inhibi- the TWEAK-TweakR system plays a role in endothelial
tion of a TWEAK-TweakR autocrine loop. This possibility cell growth and migration. This system may be important
is supported by RT-PCR data indicating that these cells for both the biological activity of the TWEAK ligand itself,
coexpress TWEAK and TweakR transcripts (data not as well as for the biological activity observed with other
shown). Failure of TweakR-Fc to inhibit the basal rate more thoroughly characterized proangiogenic mole-
of closure suggests that induction of the TweakR path- cules.
way is a required component of this autocrine loop.
Experimental ProceduresThe ability to neutralize this enhanced rate of closure is
evidence that TweakR is a required part of the activation
Cell Cultureseen by PMA and EGF. Interestingly, the basal rate of
Adult rat (Sprague-Dawley) thoracic aorta SMC were kindly providedwound closure is not significantly affected by TweakR- by M. Majesky, Baylor College of Medicine, Houston, Texas. The
Fc, demonstrating that the basal response is not depen- cells were cultured at 37C in a 1:1 mixture of Dulbecco’s modified
dent on TweakR signaling. Eagle’s medium and Ham’s F-12 medium (Mediatech) supplemented
with 5% fetal bovine serum (FBS; Hyclone Laboratories), 100 U/mlWe also found that FGF-2 angiogenic activity can be
penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin Bpartially blocked by inhibition of TweakR signaling in
(JRH Biosciences). SMC cultures were fed every 48 hr and expandedvivo (Figure 7). Again, this implies that at least in part,
by trypsin-EDTA (JRH Biosciences) treatment and subculturing ata TWEAK-TweakR interaction mediates some of the
a 1:5 split ratio. Cells were incubated for 72 hr in cell culture
FGF-2 effect. In particular, the effect of blocking medium containing 0.5% FBS to obtain a relatively quiescent SMC
TWEAK-TweakR signaling was more dramatic on vessel population. Serum-starved cells were then either left untreated or
density than it was on overall vessel area. treated with one of the following: 10 ng/ml human recombinant
FGF-2 (Bachem), 10 ng/ml human recombinant PDGF-BB (Gen-TweakR mRNA expression is induced during tissue
zyme), 2 ng/ml human recombinant TGF-1 (R&D Systems), 10 ng/regeneration, both during repair of a denuded rat artery
ml human recombinant IGF-1 (Bachem), 10% FBS, 20 ng/ml phorbol(Figure 5), and during liver regeneration (Feng et al.,
myristate acetate (PMA; Sigma), 10 ng/ml EGF (Genzyme), 10	8 M -
2000). A pattern that seems to be emerging is that thrombin (Sigma), or 10	6 M angiotensin II (Ang II; Bachem). Primary
TweakR expression is upregulated in growing or regen- human renal microvascular endothelial cells, HRMEC, were isolated,
erating tissues. Whether this expression is largely re- cultured, and used at the third passage after thawing as described
(Martin et al., 1997). All other cell lines were cultured to a densitystricted to endothelial and smooth muscle cells is not
of 2–5  105 cells per ml in RPMI medium supplemented with 10%clear. TweakR, for instance, is also present in fibroblast
fetal bovine serum, 100 g/ml streptomycin, and 100 g/ml peni-cells (Meighan-Mantha et al., 1999; Feng et al., 2000),
cillin.and TWEAK can induce a signal in astrocytes (Saas et
al., 2000). However, additional in situ hybridization data
Plasmid Construction and Expression
showing the cellular localization of TweakR expression pDC412-LZ-TWEAK, the soluble form of human TWEAK, was con-
in developing and regenerating tissues must be gener- structed with a modified leucine zipper (LZ) on the N terminus pre-
ated in order to help clarify the role of this molecule. ceded by the growth hormone leader. The construct was made
essentially like the previously described soluble LZ-CD40 ligandRegardless of its presence in cell types not directly asso-
(Fanslow et al., 1994) in the mammalian expression vector pDC412,ciated with vasculature, data presented here argue for
a derivative of pDC409 (Wiley et al., 1995) that reverses the ordera role for TweakR in vascular cell migration and angio-
of the BglII and NotI sites in the multiple cloning vector. Flag-TweakR
genesis. was created by fusing the leader sequence of the murine Ig -chain
Two other members of the TNF family have also pre- (amino acids 1–21) to a Flag synthetic epitope, and abutting to the
viously been implicated in angiogenesis: TNF and Fas N-terminal end of the mature TweakR (amino acids 35–129), which
ligand (Pandey et al., 1995; Biancone et al., 1997). How- was then placed in the pDC412 vector. TweakR-Fc was produced
by placing amino acids (1–79) of TweakR into the SalI-BglII site of theever, these effects are thought to be indirectly mediated
pDC412-Fc vector (Smith et al., 1993). Expression and purificationby production of pro-angiogenic endothelial growth fac-
of the TweakR-Fc protein was performed essentially as describedtors (Yoshizumi et al., 1992). In contrast, the proliferative
(Goodwin et al., 1993).
effect of TWEAK on endothelial cell growth is not corre-
lated with TWEAK-induced expression of known pro- Expression Cloning of TweakR cDNA
angiogenic factors or their receptors (Lynch et al., 1999). pDC409-LZ-TWEAK conditioned supernatants were produced by
This implies that the angiogenic effect of TWEAK in a transient transfection into CV1-EBNA cells. These supernatants
cornea pocket angiogenesis assay is a direct effect were incubated with magnetic beads coated with polyclonal goat
antimouse antibody (Ambion) that had previously been incubatedrather than one mediated by better characterized angio-
with a mouse monoclonal antibody against the leucine zipper (M15,genic factors such as VEGF and FGF. However, the
5 g/ml). Control beads were produced by mixing the M15 coatedeffects of some other angiogenic factors may be medi-
beads with supernatants from cells transfected with empty vector.
ated in part by TWEAK-TweakR interactions. For exam- A monolayer of COS cells, grown in a T175 flask, was transfected
ple, both FGF-2 and EGF can upregulate TweakR ex- with 15 g of DNA from a HUVEC cDNA expression library (Edge
pression in fibroblasts (Meighan-Mantha et al., 1999) Biosystems). The complexity of the DNA pools was 100,000. After
and smooth muscle cells (Figure 4). We have shown that 2 days these cells were lifted from the flask by nonenzymatic means
(Cell Dissociation Solution; Sigma) and incubated in 1.5 ml of bindingblocking TweakR signaling inhibits both EGF-stimulated
media (Goodwin et al., 1993) plus 5% nonfat dried milk for 3 hr atendothelial cell wound closure (Figure 6B) and FGF-2-
4C on a rotator wheel. Cells were precleared by adding 1 g ofinduced cornea angiogenesis (Figure 7).
control beads and rotated at 4C for an additional 45 min, after
In summary, TweakR, despite its small size, is a fully which bead-bound cells were removed with a magnet. Preclearing
functional receptor for TWEAK, capable of both binding was repeated 2 to 3 times before 1 g of the TWEAK-coated beads
TWEAK at a reasonable affinity and of transducing a was added to the cells, which were then rotated 30 min at 4C. Cells
binding the TWEAK beads were separated by use of a magnet andproliferative signal to endothelial cells. A variety of data,
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washed four times in PBS. Plasmid DNA was extracted from these at 30 g per 0.5 ml for each transfection and then incubated at
room temperature for 30 min. The transfection DNA was added tocells by lysing in 0.1% SDS and used to transform the Escherichia
coli strain DH101B. Colonies were grown 16 hr on ampicillin selective separate tubes in serum free EBM at 5 g per 0.5 ml for each
transfection. The lipid and DNA solutions were then combined tomedia. Transformants were pooled and used as a source of plasmid
DNA pools for the next round of panning. After two rounds of pan- make 1.0 ml of solution per transfection, which produced a solution
with a lipid-to-DNA ratio of six to one (30 g lipid to 5 g DNA). Thening, the positive clones were picked from the resulting pool using
a slide binding protocol. Slide binding was performed as described solution was then incubated for 15 min at room temperature.
Cell culture media was aspirated from all wells containing HUVEC(Goodwin et al., 1993), with the exception that TweakR positive
slides were detected by incubation with pDC412-LZ-Tweak condi- for transfection. Then 1.0 ml of the appropriate transfection solution
was added to culture wells and an additional 1.5 ml of serum freetioned supernatants followed by incubation with 125I-labeled M15
antileucine zipper. EBM was added. The transfection then proceeded at 37C for 6 hr
at 5% CO2. Upon completion of incubation, the transfection solution
was aspirated, and two washes were performed using 2.0 ml ofTRAF Binding
pyrogen free PBS per wash. EGM-2 media was added back at 2.0TRAF binding to cytoplasmic domain GST fusion proteins was per-
ml per well, and cells were incubated for 36–40 hr. Small samplesformed as described (Galibert et al., 1998) except that the 35S-labeled
of transfected cells were taken to determine the level of Flag-TWEAKTRAFs were produced using a coupled in vitro transcription and
expression by flow cytometry using M2 antiflag as a detection re-translation system (TNT Labeling Kit, Promega Corp., Madison, Wis-
agent.consin).
The remaining HUVEC were used for proliferation assays in tripli-
cate culture for each stimulation condition tested. First, anti-FlagReceptor-Ligand Binding Assays
M2 at 20g/ml per well of culture media was cross-linked with a goatEquilibrium binding isotherms between 125I-TweakR-Fc and surface
anti-mouse IgG (Southern Biotechnology Associates, Birmingham,TWEAK ligand were determined by standard methods (Smith et al.,
Alabama) at 40 g/ml. This complex was preincubated for 15 min1993). Briefly, CV1/EBNA cells transfected with full-length human
at room temperature and then added to culture (cross-linked M2).TWEAK ligand were diluted 30-fold into Raji cells (TWEAK-negative),
The culture medium was aspirated, the wells were washed onceand the suspension (1.7  107 total cells/ml) incubated with serially
with pyrogen free PBS, and EBM plus 0.05% FBS was added backdiluted 125I-TweakR-Fc (4.4  1015 cpm/mmole) in a total volume of
at 2.0 ml per well. The goat antimouse IgG alone or cross-linked150 l for 2 hr at 4C. Duplicate aliquots of suspension were sam-
M2 was then added to culture wells, and the assay was incubatedpled, free and bound 125I-TweakR-Fc determined, and the data plot-
for 3 days at 37C and 5% CO2. One day before harvest, BrdU (BrdUted in Scatchard format. Competitive inhibition assays were per-
Flow Kit; BD Pharmingen, San Diego, California) at 10 M finalformed similarly (Smith et al., 1996) with 0.1 nM 125I-TweakR-Fc
concentration was added to the cultures according to the manufac-incubated with cells and increasing concentrations of unlabeled
turer’s instructions. Cells were incubated an additional 24 hr beforeinhibitor (TweakR-Fc). Data were fitted to a single site competitive
trypsinization for assessment of BrdU incorporation. BrdU incorpo-inhibition equation (Smith et al., 1993).
ration was measured by flow cytometry using a FITC-conjugated
antiBrdU antibody supplied with the kit. BrdU mAb staining wasRNA Isolation and Northern Blot Hybridization
compared to control staining and binding results analyzed using aTotal RNA was isolated from cultured SMC using RNA Stat-60 (Tel-
FACScan (Becton Dickinson). In our hands, transfection efficienciesTest) according to the manufacturer’s instructions. Northern blot
for Flag-TweakR using Lipid 7 averaged 8%. Flow cytometric BrdUhybridization analysis was performed as described (Meighan-Man-
incorporation results were evaluated by intensity of antiBrdU mAbtha et al., 1999). The cDNA hybridization probes were mouse
binding and the percentage of the cells that bound antiBrdU mAb.TweakR/Fn14, 1.0 kb EcoRI/XhoI fragment of pBluescript/mFn14,
and human GAPDH,0.8 kb PstI/XbaI fragment of pHcGAP (Ameri-
Planar Endothelial Migration Assaycan Type Culture Collection).
Replicate circular lesions or “wounds” of 600–800 micron diameter
were generated in confluent HRMEC monolayers using a siliconArterial Injury Model and In Situ Hybridization
tipped drill press. At the time of wounding, the medium (DMEM Carotid arteries from anesthetized male Sprague-Dawley rats were
1% BSA) was supplemented with 20 ng/ml PMA (phorbol 12-myris-denuded with a balloon catheter and perfusion fixed as described
tate 13-acetate), 4 ng/ml EGF, and 0.150–5 g/ml TweakR-Fc, or a(Silverman et al., 1999). In situ hybridization was performed on en
combination of 40 ng/ml EGF and 0.150 to 5 g/ml TweakR-Fc. Asface preparations of vessel segments as described (Silverman et
a control for TweakR-Fc, some cells were treated with 5 g/ml IgG-al., 1999). A pBluescript/Fn14 plasmid containing the murine Fn14
Fc. The residual wound area was measured as a function of timecDNA sequence without the 3 untranslated region and poly(A) tail
(0–12 hr) using microscope and image analysis software (Bioquant,was constructed using standard techniques. This plasmid was lin-
Nashville, Tennessee). The relative migration rate was calculatedearized with SmaI, transcribed with T7 polymerase to make the
for each agent and combination of agents by linear regression ofantisense probe or linearized with ApaI, blunt ended with T4 DNA
residual wound area plotted over time.polymerase 1, and then transcribed with T3 polymerase to make
the sense probe. Vessel segments were treated with proteinase K
(1 g/ml) for 15 min at 37C, prehybridized for 2 hr at 55C in 0.3 M Corneal Pocket Assay
NaCl, 20 mM Tris-HCl (pH 7.5), 5mM EDTA, 1X Denhardt’s solution, Hydron pellets (Kenyon et al., 1996) incorporated sucralfate with
10% dithiothreitol, and 50% formamide, and incubated with the FGF-2 (90 ng/pellet), FGF-2 and IgG-Fc (14 g/pellet, control), or
appropriate [35S]UTP-labeled riboprobe for 16 hr at 55C. After wash- FGF-2 and TweakR-Fc (14g). The pellets were surgically implanted
ing, the slides were coated with autoradiographic emulsion (Kodak, into corneal stromal micropockets created by microdissection 1 mm
NTB2), exposed for 2 weeks, and then developed. All specimens medial to the lateral corneal limbus of 6- to 8-week-old male C57BL6
were examined under dark-field illumination after nuclear counter- mice. At the peak of neovascular response to FGF-2 (5 d), the cor-
staining with hematoxylin. Images were photographed and digitized. neas were photographed, using a Zeiss slit lamp, at an incipient
angle of 35–50 from the polar axis in the meridian containing the
pellet. Images were digitized and processed by subtractive colorBrdU Incorporation in Transfected HUVECs
Proliferating human umbilical vein endothelial cells (HUVEC) ob- filters (Adobe Photoshop 4.0) to delineate established microvessels
by hemoglobin content. Image analysis software (Bioquant) wastained from BioWhittaker-Clonetics (Walkersville, Maryland) were
grown in EGM-2 media (Clonetics) and then subjected to lipid-medi- used to calculate the fraction of the corneal image that was vascu-
larized, the vessel density within the vascularized area, and theated DNA transfection. HUVECs were plated overnight at 3  105
per well in six-well plates, in 2.0 ml of EGM-2 medium per culture. vessel density within the total cornea as described (Daniel et al.,
1999). Statistical analysis (non-paired T test) was performed usingThe following day, transfection solutions were prepared using poly-
styrene tubes. PerFect Lipid #7 (Invitrogen, Carlsbad, California) GraphPad Prism software 3.0 (GraphPad Software, Inc., San Diego,
California).was added to serum free endothelial basal media (EBM; Clonetics)
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